Viewing Study NCT04539808


Ignite Creation Date: 2025-12-26 @ 10:57 AM
Ignite Modification Date: 2025-12-31 @ 8:49 PM
Study NCT ID: NCT04539808
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-18
First Post: 2020-08-31
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
Sponsor: OHSU Knight Cancer Institute
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module